小肠细菌过度生长的治疗新进展

doi:10.3760/cma.j.issn.1007-1245.2024.09.003

摘要/Abstract

摘要：

小肠细菌过度生长（SIBO）是由多种因素引起的小肠细菌含量高于正常值，并且与肠易激综合征、炎症性肠病等多种疾病相关。目前，关于SIBO的治疗方法仍有争议。因此，本文对SIBO的治疗进行综述，包括抗菌药物、益生菌、促动力药、中草药、饮食疗法及其他治疗方法。

关键词:

小肠细菌过度生长, 利福昔明, 益生菌, 进展

Abstract:

Small intestinal bacterial overgrowth (SIBO) is defined as an increase in the bacterial content of the small intestine above the normal value and is associated with various diseases, such as irritable bowel syndrome, inflammatory diseases, etc. The treatment for SIBO is still controversial. Therefore, this article reviews treatments for SIBO, including antibiotic, probiotics, prokinetic, herbal therapy, dietary therapies, and other treatments.

Key words:

Small intestinal bacterial overgrowth, Rifaximin, Probiotics, Progress

高雯雯张翔王红尹雁惠.

小肠细菌过度生长的治疗新进展 [J]. 国际医药卫生导报, 2024, 30(9): 1418-1421.

Gao Wenwen, Zhang Xiang, Wang Hong, Yin Yanhui.

New progress in treatment of intestinal bacterial overgrowth [J]. International Medicine and Health Guidance News, 2024, 30(9): 1418-1421.

参考文献

[1] Efremova I, Maslennikov R, Poluektova E, et al. Epidemiology of small intestinal bacterial overgrowth[J].World J Gastroenterol,2023,29(22):3400-3421.DOI:10.3748/wjg.v29.i22.3400.
[2] Achufusi TGO, Sharma A, Zamora EA, et al. Small intestinal bacterial overgrowth: comprehensive review of diagnosis, prevention, and treatment methods[J].Cureus,2020,12(6):e8860.DOI:10.7759/cureus.8860.
[3] Krajicek EJ, Hansel SL. Small intestinal bacterial overgrowth: a primary care review[J].Mayo Clin Proc,2016,91(12):1828-1833.DOI:10.1016/j.mayocp.2016.07.025.
[4] 付新年,郑盛,杨涓. 肠道菌群与肠道疾病的研究进展[J]. 国际医药卫生导报,2023,29(22):3162-3165.DOI:10.3760/cma.j.issn.1007-1245.2023.22.003.
[5] Quigley EMM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review[J].Gastroenterology,2020,159(4):1526-1532.DOI:10.1053/j.gastro.2020.06.090.
[6] Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation[J].N Engl J Med,2011,364(1):22-32.DOI:10.1056/NEJMoa1004409.
[7] Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers[J].Int J Clin Pharmacol Res,1994,14(2):51-56.
[8] Darkoh C, Lichtenberger LM, Ajami N, et al. Bile acids improve the antimicrobial effect of rifaximin[J].Antimicrob Agents Chemother,2010,54(9):3618-3624.DOI:10.1128/AAC.00161-10.
[9] Ponziani FR, Zocco MA, D'Aversa F, et al. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation[J].World J Gastroenterol,2017,23(25):4491-4499.DOI:10.3748/wjg.v23.i25.4491.
[10] Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth[J].Aliment Pharmacol Ther,2017,45(5):604-616.DOI:10.1111/apt.13928.
[11] Wang J, Zhang L, Hou X. Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis[J].Expert Rev Gastroenterol Hepatol,2021,15(12):1385-1399.DOI:10.1080/17474124.2021.2005579.
[12] Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth[J].Aliment Pharmacol Ther,2007,25(7):781-786. DOI:10.1111/j.1365-2036.2007.03259.x.
[13] Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy[J].Am J Gastroenterol,2008,103(8):2031-2035.DOI:10.1111/j.1572-0241.2008.02030.x.
[14] Pimentel M, Cash BD, Lembo A, et al. Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity[J].Dig Dis Sci,2017,62(9):2455-2463.DOI:10.1007/s10620-017-4598-7.
[15] Ginnebaugh B, Chey WD, Saad R. Small intestinal bacterial overgrowth: how to diagnose and treat (and then treat again)[J].Gastroenterol Clin North Am,2020,49(3):571-587.DOI:10.1016/j.gtc.2020.04.010.
[16] Spinler JK, Taweechotipatr M, Rognerud CL, et al. Human-derived probiotic lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens[J].Anaerobe,2008,14(3):166-171.DOI:10.1016/j.anaerobe.2008.02.001.
[17] Ren D, Li C, Qin Y, et al. In vitro evaluation of the probiotic and functional potential of Lactobacillus strains isolated from fermented food and human intestine[J].Anaerobe,2014,30:1-10.DOI:10.1016/j.anaerobe.2014.07.004.
[18] Monteagudo-Mera A, Rastall RA, Gibson GR, et al. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health[J].Appl Microbiol Biotechnol,2019,103(16):6463-6472.DOI:10.1007/s00253-019-09978-7.
[19] Zhong C, Qu C, Wang B, et al. Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of current evidence[J].J Clin Gastroenterol,2017,51(4):300-311.DOI:10.1097/MCG.0000000000000814.
[20] Leventogiannis K, Gkolfakis P, Spithakis G, et al. Effect of a peparation of fur pobiotics on smptoms of ptients with iritable bwel sndrome: asociation with itestinal bcterial oergrowth[J].Probiotics Antimicrob Proteins,2019,11(2):627-634.DOI:10.1007/s12602-018-9401-3.
[21] Rao SSC, Rehman A, Yu S, et al. Brain fogginess, gas and bloating: a link between SIBO, probiotics and metabolic acidosis[J].Clin Transl Gastroenterol,2018,9(6):162.DOI:10.1038/s41424-018-0030-7.
[22] Madrid AM, Hurtado C, Venegas M, et al. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function[J].Am J Gastroenterol,2001,96(4):1251-1255.DOI:10.1111/j.1572-0241.2001.03636.x.
[23] Pimentel M, Morales W, Lezcano S, et al. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth[J].Gastroenterol Hepatol (N Y),2009,5(6):435-442.
[24] Lai PK, Roy J. Antimicrobial and chemopreventive properties of herbs and spices[J].Curr Med Chem,2004,11(11):1451-1460.DOI:10.2174/0929867043365107.
[25] Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth[J].Glob Adv Health Med,2014,3(3):16-24.DOI:10.7453/gahmj.2014.019.
[26] Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach[J].J Gastroenterol Hepatol,2010,25(2):252-258.DOI:10.1111/j.1440-1746.2009.06149.x.
[27] McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial[J].Gut,2017,66(7):1241-1251.DOI:10.1136/gutjnl-2015-311339.
[28] Zhang Y, Feng L, Wang X, et al. Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: a parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient outcomes[J].Am J Clin Nutr,2021,113(6):1531-1545.DOI:10.1093/ajcn/nqab005.
[29] Su T, Lai S, Lee A, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth[J].J Gastroenterol,2018,53(1):27-36.DOI:10.1007/s00535-017-1371-9.
[30] 张茹,李园,马金霞,等. 长期维持质子泵抑制剂治疗对老年人小肠细菌过度生长的影响分析[J]. 中华内科杂志,2020,59(9):706-710.DOI:10.3760/cma.j.cn112138-20191218- 00823.